Literature DB >> 15634757

Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.

Ximing Tang1, Weiguo Wu, Shi-Yong Sun, Ignacio I Wistuba, Waun Ki Hong, Li Mao.   

Abstract

Death-associated protein (DAP) kinase plays an important role in IFN-gamma, tumor necrosis factor (TNF)-alpha, or Fas-ligand induced apoptosis. TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF ligand family and can induce caspase-dependent apoptosis in cancer cells while sparing most of the normal cells. However, some of the cancer cell lines are insensitive to TRAIL, and such resistance cannot be explained by the dysfunction of TRAIL receptors or their known downstream targets. We reported previously that DAP kinase promoter is frequently methylated in non-small cell lung cancer (NSCLC), and such methylation is associated with a poor clinical outcome. To determine whether DAP kinase promoter methylation contributes to TRAIL resistance in NSCLC cells, we measured DAP kinase promoter methylation and its gene expression status in 11 NSCLC cell lines and correlated the methylation/expression status with the sensitivity of cells to TRAIL. Of the 11 cell lines, 1 had a completely methylated DAP kinase promoter and no detectable DAP kinase expression, 4 exhibited partial promoter methylation and substantially decreased gene expression, and the other 6 cell lines showed no methylation in the promoter and normal DAP kinase expression. Therefore, the amount of DAP kinase expression amount was negatively correlated to its promoter methylation (r = -0.77; P = 0.003). Interestingly, the cell lines without the DAP kinase promoter methylation underwent substantial apoptosis even in the low doses of TRAIL, whereas those with DAP kinase promoter methylation were resistant to the treatment. The resistance to TRAIL was reciprocally correlated to DAP kinase expression in 10 of the 11 cell lines at 10 ng/mL concentration (r = 0.91; P = 0.001). We treated cells resistant to TRAIL with 5-aza-2'-deoxycytidine, a demethylating reagent, and found that these cells expressed DAP kinase and became sensitive to TRAIL. These results suggest that DAP kinase is involved in TRAIL-mediated cell apoptosis and that a demethylating agent may have a role in enhancing TRAIL-mediated apoptosis in some NSCLC cells by reactivation of DAP kinase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15634757

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  18 in total

1.  Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.

Authors:  Gerald S Falchook; Siqing Fu; Aung Naing; David S Hong; Wei Hu; Stacy Moulder; Jennifer J Wheler; Anil K Sood; Ernesto Bustinza-Linares; Kristin L Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2013-08-02       Impact factor: 3.850

2.  DNA demethylating antineoplastic strategies: a comparative point of view.

Authors:  Stefano Amatori; Irene Bagaloni; Benedetta Donati; Mirco Fanelli
Journal:  Genes Cancer       Date:  2010-03

3.  Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.

Authors:  Sameer Mahesh; Ashish Saxena; Xuan Qiu; Roman Perez-Soler; Yiyu Zou
Journal:  Clin Lung Cancer       Date:  2010-11-01       Impact factor: 4.785

4.  Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase.

Authors:  Jun Wu; Cheng-ping Hu; Qi-hua Gu; Ye-peng Li; Min Song
Journal:  Acta Pharmacol Sin       Date:  2010-01       Impact factor: 6.150

5.  E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Authors:  Sara Ladu; Diego F Calvisi; Elizabeth A Conner; Miriam Farina; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

6.  Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.

Authors:  Constanze Zeller; Robert Brown
Journal:  Ther Adv Med Oncol       Date:  2010-09       Impact factor: 8.168

Review 7.  Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation.

Authors:  Giovanni L Gravina; Claudio Festuccia; Francesco Marampon; Vladimir M Popov; Richard G Pestell; Bianca M Zani; Vincenzo Tombolini
Journal:  Mol Cancer       Date:  2010-11-25       Impact factor: 27.401

8.  Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.

Authors:  F Christoph; C Kempkensteffen; S Weikert; J Köllermann; H Krause; K Miller; M Schostak; M Schrader
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

9.  Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Authors:  Woubalem Birmachu; Raymond M Gleason; Barbara J Bulbulian; Christie L Riter; John P Vasilakos; Kenneth E Lipson; Yuri Nikolsky
Journal:  BMC Immunol       Date:  2007-10-12       Impact factor: 3.615

10.  Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression.

Authors:  Fang Wang; Jian Xu; Quan Zhu; Xuejun Qin; Yan Cao; Jiangfang Lou; Yuqiao Xu; Xing Ke; Qing Li; Erfu Xie; Lixia Zhang; Ruihong Sun; Liang Chen; Bingliang Fang; Shiyang Pan
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.